



RECEIVED

AUG 30 2002

SEQUENCE LISTING

TECH CENTER 1600/2900

<110> YU, XIANXHANG
WAGNER, THOMAS E.

<120> THERAPEUTIC PORE-FORMING PEPTIDES

<130> 035879/0122

<140> 09/851,422

<141> 2001-05-09

<150> 60/203,063

<151> 2000-05-09

<150> 60/212,042

<151> 2000-06-16

<160> 12

<170> PatentIn Ver. 2.1

<210> 1

<211> 37

<212> PRT

<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence: Synthetic peptide

<220>

<221> MOD_RES

<222> (10)..(13)

<223> This region may be selected from the group consisting of [epsilon-gamma]-Glu, [epsilon-gamma]-Glu-[alpha-gamma]-(Glu)1-3, [epsilon-alpha]-(Phe)1-3, [epsilon-alpha]-(Tyr)1-3, [epsilon-alpha]-(Trp)1-3, [epsilon-alpha]-(Lys)1-3 and [epsilon-alpha]-(Arg)1-3.

<220>

<221> MOD_RES

<222> (22)..(25)

<223> This region may be selected from the group consisting of [epsilon-gamma]-Glu, [epsilon-gamma]-Glu-[alpha-gamma]-(Glu)1-3, [epsilon-alpha]-(Phe)1-3, [epsilon-alpha]-(Tyr)1-3, [epsilon-alpha]-(Trp)1-3, [epsilon-alpha]-(Lys)1-3 and [epsilon-alpha]-(Arg)1-3.

<220>

<221> MOD_RES

<222> (34)..(37)

<223> This region may be selected from the group consisting of [epsilon-gamma]-Glu, [epsilon-gamma]-Glu-[alpha-gamma]-(Glu)1-3, [epsilon-alpha]-(Phe)1-3, [epsilon-alpha]-(Tyr)1-3, [epsilon-alpha]-(Trp)1-3, [epsilon-alpha]-(Lys)1-3 and [epsilon-alpha]-(Arg)1-3.

<220>

<223> This molecule may encompass smaller embodiments according to the application as filed

31
2

<400> 1
Gly Phe Ile Ala Thr Leu Cys Thr Lys Xaa Xaa Xaa Xaa Val Leu Asp
1 5 10 15
Phe Gly Ile Asp Lys Xaa Xaa Xaa Xaa Leu Ile Gln Leu Ile Glu Asp
20 25 30
Lys Xaa Xaa Xaa Xaa
35

<210> 2
<211> 38
<212> PRT
<213> Artificial Sequence

<220>
<223> Description of Artificial Sequence: Synthetic
peptide

Ci
<220>
<221> MOD_RES
<222> (8)..(11)
<223> This region may be selected from the group consisting of [epsilon-
gamma]-Glu, [epsilon-gamma]-Glu-[alpha-gamma]-(Glu)1-3, [epsilon-
alpha]-(Phe)1-3, [epsilon-alpha]-(Tyr)1-3, [epsilon-alpha]
-(Trp)1-3, [epsilon-alpha]-(Lys)1-3 and [epsilon-alpha]-(Arg)1-3.

<220>
<221> MOD_RES
<222> (26)..(29)
<223> This region may be selected from the group consisting of [epsilon-
gamma]-Glu, [epsilon-gamma]-Glu-[alpha-gamma]-(Glu)1-3, [epsilon-
alpha]-(Phe)1-3, [epsilon-alpha]-(Tyr)1-3, [epsilon-alpha]
-(Trp)1-3, [epsilon-alpha]-(Lys)1-3 and [epsilon-alpha]-(Arg)1-3.

<220>
<221> MOD_RES
<222> (32)..(35)
<223> This region may be selected from the group consisting of [epsilon-
gamma]-Glu, [epsilon-gamma]-Glu-[alpha-gamma]-(Glu)1-3, [epsilon-
alpha]-(Phe)1-3, [epsilon-alpha]-(Tyr)1-3, [epsilon-alpha]
-(Trp)1-3, [epsilon-alpha]-(Lys)1-3 and [epsilon-alpha]-(Arg)1-3.

<220>
<223> This molecule may encompass smaller embodiments according
to the application as filed

<400> 2
Gly Ile Gly Ala Val Leu Lys Xaa Xaa Xaa Xaa Val Leu Thr Thr Gly
1 5 10 15
Leu Pro Ala Leu Ile Ser Trp Ile Lys Xaa Xaa Xaa Xaa Arg Lys Xaa
20 25 30
Xaa Xaa Xaa Arg Gln Gln
35

32
/

<210> 3
<211> 25
<212> PRT
<213> Entamoeba histolytica

<400> 3
Gly Phe Ile Ala Thr Leu Cys Thr Lys Val Leu Asp Phe Gly Ile Asp
1 5 10 15
Lys Leu Ile Gln Leu Ile Glu Asp Lys
20 25

<210> 4
<211> 37
<212> PRT
<213> Antheraea pernyi

<220>
<223> Cecropin A
<400> 4
Lys Trp Lys Leu Phe Lys Lys Ile Glu Lys Val Gly Gln Asn Ile Arg
1 5 10 15
Asp Gly Ile Ile Lys Ala Gly Pro Ala Val Ala Val Val Gly Gln Ala
20 25 30
Thr Gln Ile Ala Lys
35

<210> 5
<211> 35
<212> PRT
<213> Antheraea pernyi

<220>
<223> Cecropin B
<400> 5
Lys Trp Lys Ile Phe Lys Lys Ile Glu Lys Val Gly Arg Asn Ile Arg
1 5 10 15
Asn Gly Ile Ile Lys Ala Gly Pro Ala Val Ala Val Leu Gly Glu Ala
20 25 30
Lys Ala Leu
35

<210> 6
<211> 36
<212> PRT
<213> Antheraea pernyi

33
A

<220>
<223> Cecropin D

<400> 6
Trp Asn Pro Phe Lys Glu Leu Glu Lys Val Gly Gln Arg Val Arg Asp
1 5 10 15
Ala Val Ile Ser Ala Gly Pro Ala Val Ala Thr Val Ala Gln Ala Thr
20 25 30
Ala Leu Ala Lys
35

<210> 7
<211> 26
<212> PRT
<213> Apis mellifera

C1
<400> 7
Gly Ile Gly Ala Val Leu Lys Val Leu Thr Thr Gly Leu Pro Ala Leu
1 5 10 15
Ile Ser Trp Ile Lys Arg Lys Arg Gln Gln
20 25

<210> 8
<211> 27
<212> PRT
<213> Artificial Sequence

<220>
<223> Description of Artificial Sequence: Synthetic
peptide

<220>
<221> MOD_RES
<222> (26)..(27)
<223> [epsilon-gamma]-Glu-[alpha-gamma]-Glu

<400> 8
Gly Phe Ile Ala Thr Leu Cys Thr Lys Val Leu Asp Phe Gly Ile Asp
1 5 10 15
Lys Leu Ile Gln Leu Ile Glu Asp Lys Xaa Xaa
20 25

<210> 9
<211> 26
<212> PRT
<213> Artificial Sequence

<220>
<223> Description of Artificial Sequence: Synthetic
peptide

34
8

<220>
<221> MOD_RES
<222> (26)
<223> [epsilon-alpha]-Phe

<400> 9
Gly Phe Ile Ala Thr Leu Cys Thr Lys Val Leu Asp Phe Gly Ile Asp
1 5 10 15
Lys Leu Ile Gln Leu Ile Glu Asp Lys Xaa
20 25

<210> 10
<211> 27
<212> PRT
<213> Artificial Sequence

<220>
<223> Description of Artificial Sequence: Synthetic
peptide

<220>
<221> MOD_RES
<222> (18)
<223> [epsilon-alpha]-Phe

<220>
<221> MOD_RES
<222> (27)
<223> [epsilon-alpha]-Phe

<400> 10
Gly Phe Ile Ala Thr Leu Cys Thr Lys Val Leu Asp Phe Gly Ile Asp
1 5 10 15
Lys Xaa Leu Ile Gln Leu Ile Glu Asp Lys Xaa
20 25

<210> 11
<211> 28
<212> PRT
<213> Artificial Sequence

<220>
<223> Description of Artificial Sequence: Synthetic
peptide

<220>
<221> MOD_RES
<222> (22)
<223> [epsilon-gamma]-Glu

<220>
<221> MOD_RES

35
6

<222> (25)
<223> [epsilon-gamma]-Glu

<400> 11
Gly Ile Gly Ala Val Leu Lys Val Leu Thr Thr Gly Leu Pro Ala Leu
1 5 10 15

Ile Ser Trp Ile Lys Xaa Arg Lys Xaa Arg Gln Gln
20 25

<210> 12
<211> 30
<212> PRT
<213> Artificial Sequence

<220>
<223> Description of Artificial Sequence: Synthetic
peptide

C1
<220>
<221> MOD_RES
<222> (22)..(23)
<223> [epsilon-gamma]-Glu-[alpha-gamma]-Glu

<220>
<221> MOD_RES
<222> (26)..(27)
<223> [epsilon-gamma]-Glu-[alpha-gamma]-Glu

<400> 12
Gly Ile Gly Ala Val Leu Lys Val Leu Thr Thr Gly Leu Pro Ala Leu
1 5 10 15

Ile Ser Trp Ile Lys Xaa Xaa Arg Lys Xaa Xaa Arg Gln Gln
20 25 30
